Advertisement

144 volunteers take part in phase three trial of Sputnik V in Mumbai

After Covishield and Covaxin, 144 volunteers have reportedly taken part in the phase three trials of COVID-19 vaccine Sputnik V.

144 volunteers take part in phase three trial of Sputnik V in Mumbai
SHARES

The city of Mumbai has started administering the trial of a third vaccine, Sputnik V, after administering Covishield and Covaxin for the coronavirus.

Moreover, according to reports, 144 volunteers have taken the first shot of the COVID-19 vaccine in the month of January. Back in the month of November 2020, Mumbai’s hospitals participated in the second phase of the trial. In addition, 18 volunteers had registered themselves for the trial. Out of this, six of them were doctors. Following which, in January, the third phase was initiated at the hospital.

However, the trial was reportedly kept under the rugs in order to ensure privacy and confidentiality. Meanwhile, the hospital received an overwhelming response from volunteers, especially doctors from private hospitals.

Last year, back in the month of August, Sputnik V was given approval by the Russian health ministry and has been used in multiple nations for mass inoculations. Sputnik is based on a modified version of adenovirus, a common cold virus. The vector stripped of its disease-causing genes and modified to carry genetic instructions for making the coronavirus spike protein. This prompts the cells to cause an immune response which eventually protects against the SARS-CoV-2.

On the other hand, back on January 16, Maharashtra Chief Minister Uddhav Thackeray launched the COVID-19 vaccination drive in the state and inaugurated the vaccination centre at BKC. In the state, this drive is being conducted on five days every week- Monday, Wednesday, Thursday, Friday and Saturday. Moreover, 35,172 people were vaccinated on Friday till 6 pm. Overall, 52,90,474 beneficiaries have been administered the vaccine in the country so far.

RELATED TOPICS
Advertisement
MumbaiLive would like to send you latest news updates